{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:32:41Z","timestamp":1790418761603,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence nationale de la recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la sant\u00e9 et la recherche m\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association Monegasque contre les myopathies"},{"name":"Duchenne Parent project France"},{"name":"Fondation UVSQ"},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["PLP20161036676"],"award-info":[{"award-number":["PLP20161036676"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.omtn.2019.11.020","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T19:52:32Z","timestamp":1574797952000},"page":"371-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Philippine","family":"Aupy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Echevarr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Relizani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Zarrouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Haeberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Komisarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tensorer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Jouvion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedor","family":"Svinartchouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Goyenvalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2019.11.020_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtn.2019.11.020_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.11.020_bib3","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1093\/nar\/gku142","article-title":"Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides","volume":"42","author":"Burdick","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.11.020_bib4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","article-title":"Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts","volume":"44","author":"Burel","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.11.020_bib5","doi-asserted-by":"crossref","first-page":"30377","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2019.11.020_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kft278","article-title":"Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice","volume":"138","author":"Kakiuchi-Kiyota","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.omtn.2019.11.020_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/nat.2015.0576","article-title":"Development of a Method for Profiling Protein Interactions with LNA-Modified Antisense Oligonucleotides Using Protein Microarrays","volume":"26","author":"Kakiuchi-Kiyota","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2019.11.020_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2019.11.020_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","article-title":"Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model","volume":"8","author":"Relizani","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2019.11.020_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2019.11.020_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.omtn.2017.02.009","article-title":"Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment","volume":"7","author":"Robin","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2019.11.020_bib12","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1021\/ja025569+","article-title":"Watson-Crick base-pairing properties of tricyclo-DNA","volume":"124","author":"Renneberg","year":"2002","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2019.11.020_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/nar\/gkq733","article-title":"Position-dependent effects on stability in tricyclo-DNA modified oligonucleotide duplexes","volume":"39","author":"Ittig","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.11.020_bib14","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1093\/nar\/gks273","article-title":"TricycloDNA-modified oligo-2\u2032-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry","volume":"40","author":"Murray","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.11.020_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/nat.2018.0775","article-title":"Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington\u2019s Disease","volume":"29","author":"Imbert","year":"2019","journal-title":"Nucleic Acid Ther."},{"issue":"Suppl 1","key":"10.1016\/j.omtn.2019.11.020_bib16","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0960-8966(02)00086-X","article-title":"Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy","volume":"12","author":"Aartsma-Rus","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2019.11.020_bib17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1089\/hum.2006.061","article-title":"Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle","volume":"18","author":"Arechavala-Gomeza","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2019.11.020_bib18","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/nar\/gkf412","article-title":"Antisense properties of tricyclo-DNA","volume":"30","author":"Renneberg","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.11.020_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/nat.2018.0773","article-title":"Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model","volume":"29","author":"Echevarr\u00eda","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2019.11.020_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/nat.2015.0593","article-title":"Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics","volume":"26","author":"Henry","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2019.11.020_bib21","first-page":"810","article-title":"Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action","volume":"281","author":"Henry","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.omtn.2019.11.020_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.114.219378","article-title":"Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans","volume":"351","author":"Shen","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.omtn.2019.11.020_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/oli.1.1997.7.503","article-title":"Inhibition of coagulation by a phosphorothioate oligonucleotide","volume":"7","author":"Henry","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.omtn.2019.11.020_bib24","series-title":"Advances in Nucleic Acid Therapeutics","first-page":"474","article-title":"Preclinical and clinical drug-metabolism, pharmacokinetics and safety of therapeutic oligonucleotides","author":"Andersson","year":"2019"},{"key":"10.1016\/j.omtn.2019.11.020_bib25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.20140391","article-title":"Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators","volume":"212","author":"Flierl","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2019.11.020_bib26","doi-asserted-by":"crossref","first-page":"e0187574","DOI":"10.1371\/journal.pone.0187574","article-title":"Assessing single-stranded oligonucleotide drug-induced effects in\u00a0vitro reveals key risk factors for thrombocytopenia","volume":"12","author":"Sewing","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2019.11.020_bib27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood-2013-01-478966","article-title":"Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4","volume":"122","author":"Jaax","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2019.11.020_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/108729001300338681","article-title":"Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys","volume":"11","author":"Webb","year":"2001","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.omtn.2019.11.020_bib29","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy","volume":"25","author":"Echigoya","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2019.11.020_bib30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0192623313505781","article-title":"Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide","volume":"42","author":"Frazier","year":"2014","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtn.2019.11.020_bib31","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1021\/acs.nanolett.5b00490","article-title":"Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides","volume":"15","author":"Ezzat","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2019.11.020_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1006\/bbrc.1997.7328","article-title":"Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy","volume":"238","author":"Araki","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253119303762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253119303762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:58:54Z","timestamp":1715983134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253119303762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":32,"alternative-id":["S2162253119303762"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2019.11.020","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2019.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}